B-intervention	0	7	Hormone
I-intervention	8	19	replacement
I-intervention	20	27	therapy
O	28	33	after
O	34	40	breast
O	41	47	cancer
O	47	48	:
O	49	51	10
O	52	56	year
O	57	63	follow
O	64	66	up
O	67	69	of
O	70	73	the
B-location	74	83	Stockholm
O	84	94	randomised
O	95	100	trial
O	100	101	.

O	102	105	The
O	106	116	management
O	117	119	of
O	120	128	hormonal
O	129	139	deficiency
O	140	148	symptoms
O	149	151	in
O	152	158	breast
O	159	165	cancer
O	166	175	survivors
O	176	178	is
O	179	181	an
O	182	190	unsolved
O	191	198	problem
O	198	199	.

O	200	205	While
O	206	213	hormone
O	214	225	replacement
O	226	233	therapy
O	234	235	(
O	235	238	HRT
O	238	239	)
O	240	243	may
O	244	252	increase
O	253	256	the
O	257	261	risk
O	262	264	of
O	265	271	breast
O	272	278	cancer
O	279	281	in
O	282	289	healthy
O	290	295	women
O	295	296	,
O	297	300	its
O	301	308	effects
O	309	311	on
O	312	322	recurrence
O	323	325	is
O	326	333	unclear
O	333	334	.

O	335	348	Observational
O	349	356	studies
O	357	361	have
O	362	371	suggested
O	372	381	decreased
O	382	392	recurrence
O	393	398	rates
O	399	403	from
O	404	407	HRT
O	407	408	.

O	409	412	The
O	413	416	few
O	417	425	clinical
O	426	432	trials
O	433	435	in
O	436	440	this
O	441	446	field
O	447	451	have
O	452	455	all
O	456	460	been
O	461	467	closed
O	468	475	preterm
O	475	476	.

O	477	480	The
O	481	490	Stockholm
O	491	496	trial
O	497	500	was
O	501	508	started
O	509	511	in
O	512	516	1997
O	517	520	and
O	521	529	designed
O	530	532	to
O	533	541	minimise
O	542	545	the
O	546	550	dose
O	551	553	of
O	554	565	progestogen
O	566	568	in
O	569	572	the
O	573	576	HRT
O	577	580	arm
O	580	581	.

O	582	589	Disease
O	589	590	-
O	590	594	free
O	595	600	women
O	601	605	with
O	606	607	a
O	608	615	history
O	616	618	of
O	619	625	breast
O	626	632	cancer
O	633	637	were
O	638	648	randomised
O	649	651	to
O	652	655	HRT
O	656	657	(
O	657	658	n
O	658	659	=
B-intervention-participants	659	662	188
O	662	663	)
O	664	666	or
B-control	667	669	no
I-control	670	673	HRT
O	674	675	(
O	675	676	n
O	676	677	=
B-control-participants	677	680	190
O	680	681	)
O	681	682	.

O	683	686	The
O	687	692	trial
O	693	696	was
O	697	704	stopped
O	705	707	in
O	708	712	2003
O	713	717	when
O	718	725	another
O	726	733	Swedish
O	734	739	study
O	740	741	(
O	741	747	HABITS
O	747	748	,
O	749	752	the
O	753	761	Hormonal
O	762	773	Replacement
O	774	779	After
O	780	786	Breast
O	787	793	Cancer
O	794	795	-
O	796	798	Is
O	799	801	it
O	802	806	Safe
O	806	807	?
O	807	808	)
O	809	817	reported
O	818	827	increased
O	828	838	recurrence
O	838	839	.

O	840	847	However
O	848	851	the
O	852	861	Stockholm
O	862	870	material
O	871	877	showed
O	878	880	no
O	881	887	excess
O	888	892	risk
O	893	898	after
O	899	900	4
O	901	906	years
O	907	909	of
O	910	916	follow
O	916	917	-
O	917	919	up
O	919	920	.

O	921	922	A
O	923	927	long
O	928	932	term
O	933	939	follow
O	939	940	-
O	940	942	up
O	943	946	has
O	947	950	now
O	951	955	been
O	956	965	performed
O	965	966	.

O	967	972	After
O	973	975	10
O	975	976	.
O	976	977	8
O	978	983	years
O	984	986	of
O	987	993	follow
O	993	994	-
O	994	996	up
O	996	997	,
O	998	1003	there
O	1004	1007	was
O	1008	1010	no
O	1011	1021	difference
O	1022	1024	in
B-outcome	1025	1028	new
I-outcome	1029	1035	breast
I-outcome	1036	1042	cancer
I-outcome	1043	1049	events
O	1049	1050	:
B-iv-bin-abs	1051	1053	60
O	1054	1056	in
O	1057	1060	the
O	1061	1064	HRT
O	1065	1070	group
O	1071	1077	versus
B-cv-bin-abs	1078	1080	48
O	1081	1086	among
O	1087	1095	controls
O	1096	1097	(
O	1097	1103	hazard
O	1104	1109	ratio
O	1110	1111	(
O	1111	1113	HR
O	1113	1114	)
O	1114	1115	=
O	1115	1116	1
O	1116	1117	.
O	1117	1118	3
O	1118	1119	;
O	1120	1122	95
O	1122	1123	%
O	1124	1134	confidence
O	1135	1143	interval
O	1144	1145	(
O	1145	1147	CI
O	1147	1148	)
O	1148	1149	=
O	1149	1150	0
O	1150	1151	.
O	1151	1152	9
O	1152	1153	-
O	1153	1154	1
O	1154	1155	.
O	1155	1156	9
O	1156	1157	)
O	1157	1158	.

O	1159	1164	Among
O	1165	1170	women
O	1171	1173	on
O	1174	1177	HRT
O	1177	1178	,
B-iv-bin-abs	1179	1181	11
O	1182	1185	had
B-outcome	1186	1191	local
I-outcome	1192	1202	recurrence
O	1203	1206	and
B-iv-bin-abs	1207	1209	12
B-outcome	1210	1217	distant
I-outcome	1218	1228	metastases
O	1229	1235	versus
B-cv-bin-abs	1236	1238	15
O	1239	1242	and
B-cv-bin-abs	1243	1245	12
O	1246	1249	for
O	1250	1253	the
O	1254	1262	controls
O	1262	1263	.

O	1264	1269	There
O	1270	1274	were
B-iv-bin-abs	1275	1277	14
B-outcome	1278	1284	contra
I-outcome	1284	1285	-
I-outcome	1285	1292	lateral
I-outcome	1293	1299	breast
I-outcome	1300	1307	cancers
O	1308	1310	in
O	1311	1314	the
O	1315	1318	HRT
O	1319	1324	group
O	1325	1328	and
B-cv-bin-abs	1329	1333	four
O	1334	1336	in
O	1337	1340	the
O	1341	1348	control
O	1349	1354	group
O	1355	1356	(
O	1356	1358	HR
O	1358	1359	=
O	1359	1360	3
O	1360	1361	.
O	1361	1362	6
O	1362	1363	;
O	1364	1366	95
O	1366	1367	%
O	1368	1370	CI
O	1370	1371	=
O	1371	1372	1
O	1372	1373	.
O	1373	1374	2
O	1374	1375	-
O	1375	1377	10
O	1377	1378	.
O	1378	1379	9
O	1379	1380	;
O	1381	1382	p
O	1382	1383	=
O	1383	1384	0
O	1384	1385	.
O	1385	1388	013
O	1388	1389	)
O	1389	1390	.

O	1391	1393	No
O	1394	1405	differences
O	1406	1408	in
B-outcome	1409	1418	mortality
I-outcome	1419	1421	or
I-outcome	1422	1425	new
I-outcome	1426	1433	primary
I-outcome	1434	1446	malignancies
O	1447	1451	were
O	1452	1457	found
O	1457	1458	.

O	1459	1462	The
B-outcome	1463	1469	number
I-outcome	1470	1472	of
I-outcome	1473	1476	new
I-outcome	1477	1483	events
O	1484	1487	did
O	1488	1491	not
O	1492	1498	differ
O	1499	1512	significantly
O	1513	1520	between
O	1521	1527	groups
O	1527	1528	,
O	1529	1531	in
O	1532	1540	contrast
O	1541	1543	to
O	1544	1552	previous
O	1553	1560	reports
O	1560	1561	.

O	1562	1565	The
O	1566	1575	increased
B-outcome	1576	1586	recurrence
O	1587	1589	in
O	1590	1596	HABITS
O	1597	1600	has
O	1601	1605	been
O	1606	1616	attributed
O	1617	1619	to
O	1620	1626	higher
O	1627	1638	progestogen
O	1639	1647	exposure
O	1647	1648	.

O	1649	1651	As
O	1652	1656	both
O	1657	1663	trials
O	1664	1668	were
O	1669	1680	prematurely
O	1681	1687	closed
O	1687	1688	,
O	1689	1693	data
O	1694	1696	do
O	1697	1700	not
O	1701	1706	allow
O	1707	1711	firm
O	1712	1723	conclusions
O	1723	1724	.

O	1725	1729	Both
O	1730	1737	studies
O	1738	1743	found
O	1744	1746	no
O	1747	1756	increased
B-outcome	1757	1766	mortality
O	1767	1771	from
O	1772	1778	breast
O	1779	1785	cancer
O	1786	1788	or
O	1789	1794	other
O	1795	1801	causes
O	1802	1806	from
O	1807	1810	HRT
O	1810	1811	.

O	1812	1819	Current
O	1820	1830	guidelines
O	1831	1840	typically
O	1841	1849	consider
O	1850	1853	HRT
O	1854	1869	contraindicated
O	1870	1872	in
O	1873	1879	breast
O	1880	1886	cancer
O	1887	1896	survivors
O	1896	1897	.

O	1898	1906	Findings
O	1907	1914	suggest
O	1915	1919	that
O	1919	1920	,
O	1921	1923	in
O	1924	1928	some
O	1929	1934	women
O	1935	1942	symptom
O	1943	1949	relief
O	1950	1953	may
O	1954	1962	outweigh
O	1963	1966	the
O	1967	1976	potential
O	1977	1982	risks
O	1983	1985	of
O	1986	1989	HRT
O	1989	1990	.
